Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

The Business Research Company's Primary Biliary Cholangitis Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ...

Topline data were announced from a phase 2b/3 trial evaluating saroglitazar in patients with PBC who had an inadequate response or intolerance to UDCA.

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher ...

Discover a study exploring how verbal instructions and symptom expectations influence fatigue and motivation in people living with primary biliary cholangitis.

Intercept Pharmaceuticals, a wholly-owned biopharmaceutical subsidiary of Italy’s privately-held Alfasigma, has announced its ...